Roger Tung, Concert Pharmaceuticals CEO
May 23, 2022 10:56 AM EDT
R&D

One tri­al down, one to go as Con­cert Phar­ma­ceu­ti­cals tunes up PhI­II win for alope­cia drug

Paul Schloesser

Associate Editor

Just two months ago, Con­cert Phar­ma­ceu­ti­cals of­floaded most of its CNS pipeline to tiny Ter­ran Bio­sciences as a make-or-break da­ta read­out was well on its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times